Read today's Portuguese stories delivered to your email.
The European Commission has authorised the antibody Lecanemab as the first therapy in Europe that targets the underlying process of Alzheimer’s, rather than only treating symptoms.
By PA/TPN, in Europe, World, Health · 07 Jun 2025, 09:31 · 0 Comments
This medication is designed for treatment in the early stages and is the first of its kind to be approved in the EU by the Commission.
The main measures of efficiency of Lecanemab were the change in cognitive and functional symptoms after 18 months, which was measured using the dementia rating scale.
Share this article: Share
In Europe, World, Environment - 02 Aug 2025, 13:31
In Europe, World, Environment, Sustainability - 02 Aug 2025, 11:31
We are proud to provide our readers from around the world with independent, honest and unbiased news for free – both online and in print.
Our dedicated team supports the local community, foreign residents and visitors of all nationalities through our newspaper, website, social media and our newsletter.
We appreciate that not everyone can afford to pay for our services but if you are able to, we ask you to support The Portugal News by making a contribution – no matter how small.
Be the first to comment on this article
In Europe, World, Environment - 02 Aug 2025, 13:31
In Europe, World, Environment, Sustainability - 02 Aug 2025, 11:31
In Europe, World, Environment - 02 Aug 2025, 10:31
In Europe, World, Environment, Sustainability - 02 Aug 2025, 09:31
In Europe, World, Environment, Sustainability - 26 Jul 2025, 11:31
English
Nederlands
Deutsch
Français
Español
Italiano
Svenska
Pусский
Română
中文
Türkçe
हिन्दी
Português
Українська
اردو
Polski
عربي
Suomi
עִברִית
Português (Brasil)
